BR112016019733A2 - - Google Patents

Info

Publication number
BR112016019733A2
BR112016019733A2 BR112016019733A BR112016019733A BR112016019733A2 BR 112016019733 A2 BR112016019733 A2 BR 112016019733A2 BR 112016019733 A BR112016019733 A BR 112016019733A BR 112016019733 A BR112016019733 A BR 112016019733A BR 112016019733 A2 BR112016019733 A2 BR 112016019733A2
Authority
BR
Brazil
Application number
BR112016019733A
Other languages
Portuguese (pt)
Other versions
BR112016019733B1 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112016019733A2 publication Critical patent/BR112016019733A2/pt
Publication of BR112016019733B1 publication Critical patent/BR112016019733B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112016019733-0A 2014-02-28 2015-02-27 Composto derivado de n2-fenil-pirido[3,4-d]pirimidina-2,8-diamina, composição farmacêutica, uso de um composto para a manufatura de um medicamento para tratar um distúrbio proliferativo, e, método para sintetizar um composto BR112016019733B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1403536.4 2014-02-28
GBGB1403536.4A GB201403536D0 (en) 2014-02-28 2014-02-28 Inhibitor compounds
PCT/GB2015/050590 WO2015128676A1 (en) 2014-02-28 2015-02-27 N2-phenyl-pyrido[3,4-d]pyrimidine-2,8-diamine derivatives and their use as mps1 inhibitors

Publications (2)

Publication Number Publication Date
BR112016019733A2 true BR112016019733A2 (pt-PT) 2017-08-15
BR112016019733B1 BR112016019733B1 (pt) 2022-12-20

Family

ID=50490546

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016019733-0A BR112016019733B1 (pt) 2014-02-28 2015-02-27 Composto derivado de n2-fenil-pirido[3,4-d]pirimidina-2,8-diamina, composição farmacêutica, uso de um composto para a manufatura de um medicamento para tratar um distúrbio proliferativo, e, método para sintetizar um composto

Country Status (11)

Country Link
US (2) US9902721B2 (pt-PT)
EP (2) EP3575299B1 (pt-PT)
JP (1) JP6440728B2 (pt-PT)
CN (1) CN106459035B (pt-PT)
AU (1) AU2015221956B2 (pt-PT)
BR (1) BR112016019733B1 (pt-PT)
CA (1) CA2939058C (pt-PT)
ES (2) ES2926641T3 (pt-PT)
GB (1) GB201403536D0 (pt-PT)
RU (1) RU2693460C2 (pt-PT)
WO (1) WO2015128676A1 (pt-PT)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
GB201522532D0 (en) * 2015-12-21 2016-02-03 Cancer Rec Tech Ltd Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
DK3546456T3 (da) * 2016-11-28 2022-03-07 Teijin Pharma Ltd Krystal af pyrido[3, 4-d]pyrimidinderivat eller solvat deraf
CN110036012B (zh) * 2016-11-28 2022-05-10 帝人制药株式会社 吡啶并[3,4-d]嘧啶衍生物及其药学上可接受的盐
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
CN110799183A (zh) * 2017-06-20 2020-02-14 癌症研究所:皇家癌症医院 方法和医疗用途
GB201809458D0 (en) 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
GB201809460D0 (en) 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
KR20200110250A (ko) * 2019-03-13 2020-09-23 보로노이바이오 주식회사 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 약학적 조성물
JP7236204B2 (ja) 2019-06-28 2023-03-09 ダイハツ工業株式会社 コンソールボックス
CN115385840B (zh) * 2022-09-05 2024-07-02 北京京宇复瑞科技集团有限责任公司 制备3-甲氧基氮杂环丁烷盐酸盐的方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2697710A (en) 1953-01-02 1954-12-21 Burroughs Wellcome Co Pyrido (2,3-d) pyrimidines and method of preparing same
US3021332A (en) 1954-01-04 1962-02-13 Burroughs Wellcome Co Pyrido (2, 3-d) pyrimidine compounds and method of making
DK0790997T3 (da) 1994-11-14 2000-08-21 Warner Lambert Co 6-Aryl-pyrido[2,3-d]pyrimidiner og napthyridiner til hæmning af protein-tyrosin-kinase-fremkaldt celleproliferation
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
DK1553097T3 (da) 1999-02-10 2010-12-13 Astrazeneca Ab Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
CZ20022475A3 (cs) 2000-01-25 2003-03-12 Warner-Lambert Company Pyrido[2,3-d]pyrimidin-2,7-diaminové inhibitory kinázy
US7053070B2 (en) 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US7030123B2 (en) 2000-05-31 2006-04-18 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
WO2002090360A1 (en) 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030105115A1 (en) 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CA2470214A1 (en) 2001-12-13 2003-06-26 Abbott Laboratories 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
PL372886A1 (en) 2002-03-07 2005-08-08 F.Hoffmann-La Roche Ag Bicyclic pyridine and pyrimidine p38 kinase inhibitors
US20040092521A1 (en) 2002-11-12 2004-05-13 Altenbach Robert J. Bicyclic-substituted amines as histamine-3 receptor ligands
MXPA05005116A (es) 2002-11-12 2005-07-01 Abbott Lab Aminas biciclicas sustituidas en la forma de ligandos del receptor de histamina-3.
DE602004021558D1 (de) 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
JP4189492B2 (ja) 2004-03-22 2008-12-03 独立行政法人物質・材料研究機構 層状複水酸化物/ゼオライト複合体
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20050256118A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
SI1899322T1 (sl) 2005-06-28 2010-01-29 Sanofi Aventis Izokinolinski derivati kot inhibitorji Rho-kinaze
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
EP2024342A2 (en) 2006-05-01 2009-02-18 Pfizer Products Incorporated Substituted 2-amino-fused heterocyclic compounds
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
MX2009006627A (es) 2006-12-22 2009-08-12 Novartis Ag Quinazolinas para la inhibicion de pdk1.
WO2008135232A1 (en) 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
AU2008290330A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of TTK/Mps1 for the treatment of proliferative disorders
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
US20100311965A1 (en) 2007-12-28 2010-12-09 Carna Biosciences Inc. 2-aminoquinazoline derivative
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
US9334242B2 (en) 2008-06-16 2016-05-10 Gtx, Inc. Compounds for treatment of cancer
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン, エルエルシー 複素環式化合物およびその使用
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2598508B1 (en) 2010-07-30 2015-04-22 Nerviano Medical Sciences S.r.l. Isoxazolo-quinazolines as modulators of protein kinase activity
ES2377610B1 (es) 2010-09-01 2013-02-05 Institut Químic de Sarriá CETS Fundació Privada Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos.
EP2630136A1 (en) 2010-10-21 2013-08-28 Universität des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8623889B2 (en) 2010-12-17 2014-01-07 Genentech, Inc. Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
WO2012092471A2 (en) 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
WO2012101032A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
GB201104267D0 (en) * 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US9745191B2 (en) 2011-04-11 2017-08-29 Saudi Arabian Oil Company Auto thermal reforming (ATR) catalytic structures
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
JP5928960B2 (ja) 2013-06-04 2016-06-01 国立大学法人佐賀大学 イオン吸着材の製造方法
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds

Also Published As

Publication number Publication date
CA2939058C (en) 2022-04-26
ES2926641T3 (es) 2022-10-27
BR112016019733B1 (pt) 2022-12-20
AU2015221956B2 (en) 2019-05-09
US20180194761A1 (en) 2018-07-12
JP2017506661A (ja) 2017-03-09
EP3110816B1 (en) 2019-06-19
RU2016137789A (ru) 2018-04-03
EP3575299A1 (en) 2019-12-04
US9902721B2 (en) 2018-02-27
CA2939058A1 (en) 2015-09-03
CN106459035A (zh) 2017-02-22
JP6440728B2 (ja) 2018-12-19
RU2016137789A3 (pt-PT) 2018-10-23
CN106459035B (zh) 2018-04-06
GB201403536D0 (en) 2014-04-16
EP3575299B1 (en) 2022-07-20
US10399974B2 (en) 2019-09-03
WO2015128676A1 (en) 2015-09-03
ES2739148T3 (es) 2020-01-29
US20160362409A1 (en) 2016-12-15
AU2015221956A1 (en) 2016-07-07
RU2693460C2 (ru) 2019-07-03
EP3110816A1 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
BR112016021603A2 (pt-PT)
BR112016027265A2 (pt-PT)
BR112016026285A2 (pt-PT)
BR112016025523A2 (pt-PT)
BR112016019459A2 (pt-PT)
BR112016021745A2 (pt-PT)
BR112016026693A2 (pt-PT)
BR112016018578A2 (pt-PT)
BR112016026124A2 (pt-PT)
BR112016018800A2 (pt-PT)
BR112016027611A2 (pt-PT)
BR112016026638A2 (pt-PT)
RU2016137789A3 (pt-PT)
BR112016022869A2 (pt-PT)
BR112016030436A2 (pt-PT)
BR112016022959A2 (pt-PT)
BR112016018694A2 (pt-PT)
BR112016027188A2 (pt-PT)
BR112016026793A2 (pt-PT)
BR112016018728A2 (pt-PT)
BR112016026642A2 (pt-PT)
BR112016021805A2 (pt-PT)
BR112016018896A2 (pt-PT)
BR112016016199A2 (pt-PT)
BR122020011353A2 (pt-PT)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/02/2015, OBSERVADAS AS CONDICOES LEGAIS